DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK MarketsDUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets

1 Day Clinical Trial Agreements Training Course: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets (Mar 18, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering.

The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.

This intensive short course provides essential insights into the legal framework governing clinical trials in the EU and UK, ensuring compliance, protecting intellectual property and managing liability risks.

The expert speakers will explain the dynamic and increasingly demanding regulatory and data protection landscape to better inform those negotiations and drafting these agreements.

Benefits of attending

By attending this seminar you will:

  • Learn about the regulatory framework concerning clinical trials in the EU and the UK
  • Understand the EU Clinical Trial Regulation and UK Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Examine the roles and obligations of stakeholders including sponsors, CROs, investigators, and ethics committees
  • Navigate clinical trials approval, ethical approvals, policy issues, and the legal risks of non-compliance
  • Master informed consent, clinical trial transparency, and compensation models to mitigate legal exposure
  • Learn how to protect IP rights in clinical trials, draft strong confidentiality agreements, and manage publication clauses.

Who Should Attend:

This course has been specially designed for:

  • Lawyers and in-house legal teams
  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers and professionals
  • R&D staff
  • Regulatory specialists
  • And CROs, sponsors and healthcare organisations looking to stay ahead in an evolving legal landscape.

Key Topics Covered:

Overview of the regulation of clinical trials – the legal framework governing clinical trials in the EU and the UK

  • What a clinical trial is and the types of clinical trials
  • Who the stakeholders are and their roles and obligations
  • EU regulatory framework under the Clinical Trial Regulation 536/2014/EU and the Clinical Trials Information System (CTIS)
  • UK framework post Brexit under the Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Clinical trial approval, ethics approval and policy issues (eg Health Research Authority approval)
  • What could happen if a clinical trial is not conducted in accordance with the law

Consent, data and IP rights

Sponsors and CROs must meet obligations relating to transparency, participant consent and data protection in clinical trials. In turn, those obligations have an impact on parties’ liability risks and IP rights. This session will examine:

  • Participant consent and liability risks:
    • Transparency obligations and the publication of clinical trials outcomes
    • How transparency and consent interact with liability risks, including:
      • Compensation models
      • Clinical trials insurance
      • Product liability risks for licensed products
  • Data protection:
    • Overview of the requirements
    • Use of patient data during and after a clinical trial (particularly in light of the 3/2019 guidance from the European Data Protection Board)
  • Intellectual property rights:
    • Relevant IP rights associated with clinical trials
    • How to best protect any accruing IP rights
    • Drafting and negotiating of IP rights, confidentiality and publication clauses

Final questions

For more information about this training visit https://www.researchandmarkets.com/r/6n17d8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
1 Logo
1 Price(1)
$0.007874
$0.007874$0.007874
+0.43%
USD
1 (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44
Putin Claims U.S. Wants to Use Europe’s Largest Nuclear Plant for Bitcoin Mining

Putin Claims U.S. Wants to Use Europe’s Largest Nuclear Plant for Bitcoin Mining

Russian President Vladimir Putin has claimed that the United States proposed using Europe’s largest nuclear power plant to mine Bitcoin and other cryptocurrencies as part of ongoing peace negotiations, according to a report by Kommersant, one of Russia’s leading business newspapers.
Share
MEXC NEWS2025/12/27 23:13
Analysts See XRP Trading Sideways in 2026 as Market Awaits New Catalysts

Analysts See XRP Trading Sideways in 2026 as Market Awaits New Catalysts

Market analysts expect XRP to trade largely sideways through 2026, with price action characterized by range‑bound consolidation unless new, material bullish catalysts emerge.
Share
MEXC NEWS2025/12/27 23:11